Genmab — November 2016
-
De har lige præsenteret positive resultater af et fase 2a studie i guselkumab i samarbejde med Janssen(!). Måske skal pengene bruges til fase 3 studiet. https://www.morphosys.com/media-investors/media-center/morphosys-announces-that-its-licensee-janssen-has-presented-positive
-
Det er så et andet studie pengene skal bruges til: "The funds we have raised will allow us to further develop our proprietary portfolio, for example taking our anti-CD19 antibody MOR208 into a pivotal phase 3 study in diffuse large B cell lymphoma (DLBCL)
-
-
Roche satser benhårdt på særlig tilgang til kræftbehandling
Verdens største selskab inden for kræftmedicin, Roche, har fastsat mikroskopet på immunterapiernes store potentiale og lægger stort set alle fase 3-æg i denne kurv. MedWatch har snakket med selskabets øverste ledelse om konkurrencesituationen og rygraden i satsningen.
(medwatch.dk)
-
kommer senest 17 feb, men vi er mange her, der tror, at det kommer meget snart
-
jo, min fejl
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind